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Abstract
Syncope is a very common clinical problem. Given the extensive differential diagnosis, we have  
developed a structured approach for the evaluation and management of patients with unexplain­
ed syncope. Patients with overt cardiac, neurologic, or metabolic disturbances are identified 
and treated accordingly. However, the remaining patients with high­risk characteristics are 
hospitalized for risk stratification. After excluding patients who can benefit from pacemaker 
or implantable cardioverter-defibrillator implantation, an implantable loop recorder (ILR) 
appears to be a very effective diagnostic tool. The recent availability of a small ILR that can be 
implanted within minutes and provides daily data wirelessly for over 3 years appears to have 
elevated the ILR over short-term external electrocardiography (ECG) monitoring techniques in 
patients with unexplained syncope. Herein, using specific case examples, we review how we use 
a structural pathway at our institution to guide the evaluation and management of patients 
presenting with unexplained syncope, identify the types of patients who benefit from long-term 
ECG monitoring, and show how this strategy has positively affected clinical care in these pa­
tients. (Cardiol J 2014; 21, 6: 625–630)
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Introduction
Syncope (derived from the Greek term syn­
coptein [“to cut short”]) is a very common clinical 
problem with an overall incidence of a first report 
of syncope being 6.2 per 1,000 person-years [1]. 
The incidence rate increases with age, especially 
after age 70; the estimated 10-year cumulative in-
cidence of syncope is 6% and up to 22% of patients 
experience recurrent syncope [1]. The differential 
diagnosis of syncope is extensive [2]. Thus, a stru-
ctured approach is needed for the evaluation and 
management of patients with unexplained syncope. 
Case vignette no. 1
A 62-year-old male with hypertension (well 
controlled with valsartan 160 mg daily) presented 
to our emergency department following a syncopal 
episode. The patient was well, on his way from his 
bedroom to the kitchen, when he suffered his first-
-ever episode of syncope. There was no prodrome. 
The patient remembered heading to the kitchen; 
the next thing that he remembered was walking up 
on the floor in a pool of blood. In the emergency 
room, the patient was alert and oriented. The blood 
pressure was 130/80 mm Hg and the heart rate 
was 64 bpm and regular. There was no orthostasis. 
The physical examination was remarkable only for 
a small laceration across his forehead. His elec- 
trocardiogram (ECG) showed sinus rhythm at 
68 bpm; there was underlying left bundle branch 
block (LBBB). Routine blood tests were within 
normal limits. Does this patient require hospitali-
zation for further evaluation?
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At our institution, all patients presenting with 
transient loss of consciousness deemed to have 
had an episode of syncope are managed accor-
ding to a standardized clinical pathway (Fig. 1). 
The initial step in the process is a detailed history, 
physical examination (including assessment of 
orthostasis), basic laboratory testing (comple-
te blood cell count, chemistry profile), baseline 
12-lead ECG, and determination of the patient’s 
OESIL score [3]. Certain patients have features 
that necessitate prompt hospitalization for furt-
her evaluation. These include those with features 
suggestive of a significant neurologic event (e.g., 
subarachnoid hemorrhage, stroke, etc.), significant 
medical disturbance (e.g., severe anemia and/or 
electrolyte disturbance), or obvious cardiac etio-
logy (e.g., atrioventricular [AV] block, ventricular 
tachycardia, pacemaker failure, etc.).
For the remaining patients, the next step in 
the process is determining whether patients need 
to be hospitalized for further observation and 
evaluation. Current practice guidelines suggest 
prompt hospitalization when syncope occurs in 
the setting of severe structural or coronary artery 
disease (signs and symptoms of aortic stenosis, 
heart failure, prior myocardial infarction, known left 
ventricular dysfunction) and when clinical or ECG 
criteria suggest arrhythmic syncope (Table 1) [4]. 
Figure 1. A structured clinical pathway for the evaluation and management of a patient presenting to our emer-
gency department with transient loss of consciousness (TLOC) deemed to represent a syncopal episode; ARVC 
— arrhythmogenic right ventricular cardiomyopathy; BFB — bifascicular block; CBC — complete blood cell count; 
CHF — congestive heart failure; CV — cardiovascular; ECG — electrocardiogram; EF — ejection fraction; EP — elec-
trophysiology; ER — emergency room; HF — heart failure; HD — heart disease; H & P — history and physical exami-
nation;  ICD — implantable cardioverter-defibrillator; ICM — insertable cardiac monitor; MI — myocardial infarction; 
NSVT — non-sustained ventricular tachycardia; OESIL — Osservatorio Epidemiologico sulla Sincope nel Lazio; PPM — 
permanent pacemaker; PVD — peripheral vascular disease; SAH — subarachnoid hemorrhage; SCD — sudden 
cardiac death; TIA — transient ischemic attack; WPW — Wolff Parkinson White.
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We also hospitalize patients with an OESIL score 
≥ 2 since these patients have a high 1-year morta-
lity. Our patient, who had underlying LBBB, was 
hospitalized for further evaluation.
Patients in whom a decision is made to pursue 
hospitalization undergo at least 24-h of continuous 
ECG (telemetry or Holter) monitoring as well 
as baseline echocardiography. The latter identi-
fies patients who may benefit from implantable 
cardioverter-defibrillator (ICD) implantation on the 
basis of underlying structural heart disease (e.g., 
hypertrophic cardiomyopathy, arrhythmogenic 
right ventricular cardiomyopathy, left ventricular 
dysfunction) or require an intervention to relie-
ve an “obstruction to flow” (e.g., critical aortic 
stenosis, aortic dissection, severe pulmonary hy-
pertension, acute pulmonary embolism, left atrial 
myxoma, pericardial tamponade). In the remaining 
patients, the implantable loop recorder (ILR) is the 
most promising monitoring tool for helping make 
an ultimate diagnosis in patients presenting with 
unexplained syncope. The currently accepted crite-
ria for ILR implantation are summarized in Table 2.
In patients with recurrent unexplained syn-
cope, guidelines now advocate the “early” use of 
ILRs since recurrent syncope occurs sporadically 
and because ECG documentation at time of recur-
rent syncope is an extremely important diagnostic 
modality [5]. The diagnostic yield of any ECG 
monitoring strategy increases as the monitoring 
period is increased; ILRs have a significantly 
greater diagnostic yield than 24-h Holter, 30-day 
event, or 30-day ambulatory cardiovascular teleme- 
try monitoring [6]. The PICTURE registry was 
a prospective, multicenter, observational study that 
followed 570 patients with recurrent unexplained 
pre-syncope or syncope who received an ILR [7]. 
It was shown that these patients were evaluated 
on average by 3 different specialists and underwent 
a median of 13 non-diagnostic tests (range 9–20). 
Within the first year, syncope recurred in a third of 
the patients; the ILR provided a diagnosis in 78% 
of the patients, most commonly a cardiac etiology.
In some patients, an ILR may be appropriate 
following a first episode of syncope. An example is 
a patient (like ours) with unexplained syncope 
whose ECG shows bifascicular AV block (i.e., right 
bundle branch with an associated hemiblock or 
LBBB). A prior study evaluated 52 patients with 
syncope and a bundle branch block who underwent 
ILR implantation following an unremarkable initial 
evaluation, which included an electrophysiologi-
cal study [8]. Syncope recurred in 42% of these 
patients; the ILR showed that recurrent syncope 
was commonly (but not always) attributable to 
paroxysmal AV block. Our patient had a normal 
echocardiogram and underwent ILR placement; 
6 weeks later, recurrent syncope was shown to 
correlate with an episode of complete heart block 
with ventricular asystole.
Table 1. Features suggesting arrhythmic syncope. 
Adapted from [4].
Syncope during exertion or while supine
Palpitations at the time of syncope
Family history of sudden cardiac death
Non-sustained ventricular tachycardia
Bifascicular block (LBBB or RBBB combined with  
left anterior or left posterior fascicular block) or  
other intraventricular conduction abnormalities  
with QRS duration ≥ 120 ms
Severe sinus bradycardia
Manifest pre-excitation
Short or long QT interval
RBBB pattern with coved ST-elevation in  
leads V1–V2 (Brugada pattern)
Negative T waves in right precordial leads  
and epsilon waves (ARVC)
ARVC — arrhythmogenic right ventricular cardiomyopathy;  
LBBB — left bundle branch block; RBBB — right bundle branch block
Table 2. Indications for an implantable loop  
recorder (ILR) in patients with unexplained  
syncope. Adapted from [5].
Class I. ILR is indicated:
•	 In an early phase of evaluation of patients with 
recurrent syncope of uncertain origin who have 
(level of evidence: A):
 — absence of high-risk criteria that require imme-
diate hospitalization or intensive evaluation, and 
 — a likely recurrence within battery longevity  
of the device 
•	 In high-risk patients in whom a comprehensive 
evaluation did not demonstrate a cause of syncope 
or lead to specific treatment (level of evidence: B)
Class IIA. ILR may be indicated:
•	To assess the contribution of bradycardia before  
embarking on cardiac pacing in patients with 
suspected or certain neurally-mediated syncope 
presenting with frequent or traumatic syncopal 
episodes (level of evidence: B)
Class IIB. ILR may be indicated:
•	 In patients with transient loss of consciousness 
of uncertain syncopal origin in order to definitely 
exclude an arrhythmic mechanism  
(level of evidence: C)
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A multicenter, randomized, clinical trial is 
currently underway to assess whether a strategy 
of empiric permanent pacemaker implantation in 
patients with syncope (≥ 1 syncopal episode in the 
preceding year), bifascicular block, and preserved 
left ventricular function improves future outcome 
more effectively than a strategy of therapy guided 
by prolonged monitoring with an ILR [9]. The 
primary outcome measure will be a composite of 
adverse events, such as death, syncope, asympto-
matic diagnostic bradycardia, symptomatic brady-
cardia, and acute and chronic device complications; 
secondary endpoints will include syncope symp-
toms, quality of life, and economic burden. Finally, 
in patients with recurrent vasovagal syncope, the 
ILR provides information about the characteristics 
of the heart rhythm during recurrent syncope and 
may help guide decisions regarding specific therapy 
[10, 11].
A critical need in ILRs has been for the device 
to transmit acquired data of clinical significance 
wirelessly to providers. We reported the clinical 
utility of a wireless ILR, which was commercially 
available in the United States for a brief period, in 
50 consecutive patients in whom syncope was either 
recurrent, associated with trauma or an abnormal 
ECG [6]. A diagnosis was made in nearly a third 
of our patients. An arrhythmia was responsible for 
syncope in 69% of these patients; all arrhythmias 
were captured within the first 6-months of ILR 
implantation. Of note, had ECG monitoring been 
limited to 30 days (as is typical of currently available 
ambulatory external ECG monitors), the diagnosis 
would have been missed in the majority of patients. 
The most common etiology for recurrent syncope 
was a bradyarrhythmia, either due to sinus node 
dysfunction or complete heart block. We found that 
these patients frequently did not activate their ILR 
at the time of recurrent syncope. The wireless ILR 
transferred ECG data (automatically) to a central 
monitoring station within minutes to hours of the 
arrhythmic event, virtually eliminating the possi-
bility of data loss. This facilitated clinical decision 
making in these patients.
The recent release of a third generation loop 
recorder (Medtronic Reveal LINQTM) has fun-
damentally altered the landscape of diagnostic 
monitoring in patients with unexplained syncope 
[12]. This device is small (measures approxima-
tely 7 × 45 × 4 mm, or 1 cc), has an over 3-year 
battery capacity, can be implanted within minutes 
(subcutaneously 2 cm from the left lower border of 
the sternum at the fourth intercostal space and at 
a 45° angle from the plane of the sternum) using only 
local anesthesia, and wirelessly transfers acquired 
data to providers nightly. In addition, it has auto-
mated algorithms for the detection and storage of 
significant brady- and tachyarrhythmias, including 
atrial fibrillation. The following are examples of 
how this new technology has facilitated clinical 
decision making in our practice.
Case vignette no. 2
A 46-year-old male presented for evalua-
tion because of frequent episodes of palpitations 
(typically during periods of exertion) as well as 
frequent episodes of pre-syncope (typically when 
he is lying down). He denied any episodes of syn-
cope. In addition, he had a strong family history of 
sudden death. His brother died suddenly at age 25 
and his father died suddenly at age 44; an autopsy 
demonstrated a ruptured aortic aneurysm in the 
father. The patient had previously used a 30-day 
event recorder; no symptoms occurred during 
the monitoring period. Therefore, he underwent 
ILR implantation. Three weeks following the de-
vice implantation, he reported another episode of 
near-syncope while driving; the ILR recorded an 
episode of complete heart block with ventricular 
asystole (Fig. 2A). The ILR was explanted and 
a dual chamber pacemaker was implanted; the 
patient has been asymptomatic since.
Case vignette no. 3
A 70-year-old female was referred in April 
2014 for evaluation following 2 episodes of synco-
pe. She had known moderate mitral regurgitation 
and LBBB. In September 2012, she was diagnosed 
with breast cancer and underwent bilateral radical 
mastectomy followed by chemotherapy and radia-
tion. Unfortunately, in early 2014 she was diagno-
sed with acute myelogenous leukemia. While in 
the midst of chemotherapy, she had 2 episodes of 
syncope. The second episode resulted in a subdural 
hematoma, subarachnoid hemorrhage, and a lace-
ration to her forehead. An echocardiogram showed 
mild left ventricular dysfunction (ejection fraction 
40–45%); a nuclear stress test showed no perfusion 
defects and confirmed the mild left ventricular dys-
function. She was advised by another consultant to 
consider dual chamber ICD implantation. Following 
a second opinion, she received an ILR for long-term 
ECG monitoring. Four months later, she suffered 
another syncopal episode while walking from her 
bed to the bathroom. She suffered a fracture of her 
left arm. The patient’s husband immediately used 
the patient activator to store the patient’s ECG. 
No arrhythmia was recorded during the episode.
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Case vignette no. 4
An 83-year-old obese female with hyperten-
sion and diabetes was admitted following her fourth 
syncopal episode in the past 2 years. Her baseline 
ECG and echocardiogram were normal. During 
her most recent episode, she was standing in her 
kitchen talking with her daughter when she started 
to feel light-headed and then had frank syncope. 
She hit the back of her head but quickly regained 
consciousness; there was no post-ictal state. She 
received an ILR for long-term ECG monitoring. 
Four months later, she had another witnessed 
episode of syncope. Interrogation of the device 
showed an episode of abrupt sinus slowing followed 
by sinus arrest (Fig. 2B); the ILR was removed 
and a dual chamber pacemaker was implanted. The 
patient has been asymptomatic since.
Conclusions
The evaluation of the patient who presents 
with unexplained syncope should incorporate 
Figure 2. A. Transient complete heart block. The patient is in sinus rhythm. The PR interval is normal and the QRS 
complex is narrow. There is abrupt development of complete heart block with ventricular asystole; the red arrows 
mark the P waves representing the underlying and unperturbed sinus rhythm. The black arrow likely reflects myoclo-
nus occurring during a brief period of altered consciousness; B. Abrupt sinus slowing followed by sinus arrest, which 
resulted in syncope.
A
B
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a structured approach. Unfortunately, recent data 
from a survey of 43 countries suggest that only 
42% of centers had a specific standardized protocol 
or algorithm for the assessment of patients with 
unexplained syncope [13]. Thus, it is not surprising 
that there was a wide variability in the likelihood 
that patients would be hospitalized at these centers 
for further evaluation. Early risk stratification of 
patients is necessary to determine those who will 
benefit from either pacemaker or ICD implantation 
as well as to identify those patients who require 
additional medical or neurologic evaluation. In the 
remaining patients, we have found ILRs to have 
significant diagnostic utility. Surprisingly, recent 
data from a survey of 45 centers showed a relatively 
low use of ILRs in patients with recurrent synco-
pe with no underlying structural heart disease, 
in high-risk patients in whom a comprehensive 
evaluation could not clarify the cause of syncope, 
and in patients with suspected neurally-mediated 
syncope to assess the contribution of bradycardia 
before embarking on specific therapy [14]. It 
remains to be determined, however, whether the 
acceptance of the ILR will change dramatically 
given the recent availability of the miniaturized 
Reveal LINQTM system.
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